CYTODYN
CytoDyn is a biotechnology company focused on the development of new therapies to combat infections with immune deficiency viruses. It has a unique and once-in-a-lifetime opportunity to possibly impact the IV/AIDS problem facing the world. CytoDyn will diligently pursue science and business opportunities, as presented, that may eventually benefit both shareholders and the world. CytoDyn developing subcutaneously delivered humanized cell-specific monoclonal antibodies (mAbs) as entry inhibitors ... for the treatment and prevention of Human Immunodeficiency Virus (HIV). The company intends to continue to develop PRO 140 as a therapeutic anti-viral agent in persons infected with HIV. They conducting a Phase 1b/2 clinical trial to evaluate its targeted therapy for the treatment of metastatic triple-negative breast cancer, the most aggressive type of breast cancer.
CYTODYN
Industry:
Biotechnology Pharmaceutical Therapeutics
Founded:
2002-01-01
Address:
Vancouver, Washington, United States
Country:
United States
Website Url:
http://www.cytodyn.com
Total Employee:
11+
Status:
Active
Contact:
(360) 980-8524
Email Addresses:
[email protected]
Total Funding:
89.48 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Universal Analytics Font Awesome
Similar Organizations
Aclaris Therapeutics
Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Axcella
Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.
Imvax
Imvax is a biotechnology company focused on the development of novel patient-specific vaccines and immunotherapy strategies.
Jounce Therapeutics
Jounce Therapeutics is developing cancer immune-therapies to harness the immune system to attack cancerous cells and tumors.
Ribon Therapeutics
Ribon Therapeutics is a biotechnology company focused on the development of therapeutics treatments targeting stress support pathways.
Current Employees Featured
Founder
Stock Details
Key Employee Changes
Official Site Inspections
http://www.cytodyn.com Semrush global rank: 2.4 M Semrush visits lastest month: 7.63 K
- Host name: ec2-174-129-30-187.compute-1.amazonaws.com
- IP address: 174.129.30.187
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Cytodyn"
Company Information :: CytoDyn Inc. (CYDY)
Company Contact CytoDyn Inc. 1111 Main Street Suite 660 Vancouver, WA 98660 T: 360-980-8524 F: 360-799-5954See details»
Join our Team :: CytoDyn Inc. (CYDY)
Oversees Clinical Research Organization (CRO). Manages other functional service providers (non-CRO) relationships to ensure work is being performed in accordance with contract …See details»
Cytodyn - Crunchbase Company Profile & Funding
CytoDyn is a biotechnology company focused on the development of new therapies to combat infections with immune deficiency viruses. It has a unique and once-in-a-lifetime opportunity to …See details»
CytoDyn - LinkedIn
CytoDyn | 2,944 followers on LinkedIn. CytoDyn’s purpose is to help enhance the lives of patients with life-threatening diseases. | CytoDyn is in late-stage clinical development of leronlimab, a ...See details»
CytoDyn Engages Syneos Health as CRO For Its Phase …
VANCOUVER, Washington, Oct. 04, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the ...See details»
Cytodyn - Funding, Financials, Valuation & Investors - Crunchbase
CytoDyn is a biotechnology company that focuses on the development of new therapies to combat infections with immune deficiency viruses. Search Crunchbase. ... How much funding …See details»
CytoDyn Engages Leading CRO For Phase II Inflammation Trial
VANCOUVER, Washington, Aug. 23, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a biotechnology company developing leronlimab, a …See details»
CytoDyn Engages Syneos Health as CRO For Its Phase II
Oct 4, 2024 CytoDyn is a clinical-stage biotechnology company focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody …See details»
CytoDyn Announces Company Updates and …
Jul 11, 2023 CytoDyn is a clinical-stage biotechnology company focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody (mAb) that is designed to bind to C-C chemokine …See details»
CytoDyn Announces Treatment of the First Patient in its Pivotal …
Sep 10, 2021 An interim analysis will be conducted 28 days following enrollment of 245 patients (40% of targeted trial patients) VANCOUVER, Washington, Sept. 09, 2021 (GLOBE …See details»
CytoDyn Inc. (CYDY) Stock Price, News, Quote & History - Yahoo …
CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of …See details»
CytoDyn Announces FDA Clearance of Its Phase II Oncology Trial
Syneos Health® is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. Syneos Health translates unique clinical, medical affairs and ...See details»
CytoDyn Engages Syneos Health as CRO For Its Phase II Oncology …
Oct 4, 2024 --CytoDyn Inc., a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that it has engaged …See details»
Meet CytoDyn :: CytoDyn Inc. (CYDY)
Meet CytoDyn. The Next Generation of Monoclonal Antibody Therapy. CytoDyn is committed to enhancing the lives of patients through target specific medicine. Our team is focused on …See details»
CytoDyn to Host Webcast to Provide Company Update - Yahoo …
VANCOUVER, Washington, May 28, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a …See details»
CytoDyn Announces the Addition of Leading Experts in
May 13, 2022 CytoDyn is a clinical-stage biotechnology company focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody …See details»
Our Science :: CytoDyn Inc. (CYDY)
HIV. Thirty-seven million people are currently living with HIV. While daily oral antiretroviral therapy limits HIV replication, its use is a lifelong requirement and increases the likelihood for the …See details»
CytoDyn Announces Favorable Ruling Granting Injunction Against …
Dec 22, 2021 CytoDyn recently completed a Phase 2 clinical trial with leronlimab in mTNBC and a Phase 2 basket trial in solid tumor cancers (22 different cancer indications) A Phase 2 …See details»
CytoDyn Announces Company Updates and Investment …
Jul 11, 2023 Claim Filed in Former CRO Litigation for Damages Exceeding $100M Dr. Arman Returns from Medical Leave as SVP of Business Operations Webcast to be held Monday, July …See details»